The Centers for Medicare and Medicaid Services (CMS) plans to significantly reduce reimbursement for dual-energy X-ray absorptiometry (DXA),—used to measure bone density, diagnose osteoporosis and help prevent fractures—performed as a hospital outpatient service in the 2017 Hospital Outpatient Prospective Payment System (HOPPS). If finalized, by 2023 it will cut payment for the DXA testing by 37%.
Also by this Author
Where the ACR Stands & Why
The reduction follows a 75% decline in reimbursement for DXA performed in physicians’ offices since 2006. The ACR has worked with a coalition of state rheumatology societies, professional organizations and advocacy groups to author a letter to the CMS expressing opposition to these new cuts. The letter’s long list of authors includes the Black Women’s Health Imperative, the Philadelphia Rheumatism Society and the United States Bone and Joint Imperative.
Although randomized controlled trials have not shown that DXA testing prevents fractures, indirect and observational evidence shows that it “saves lives and money,” says ACR member and incoming chair of the Government Affairs Committee, Angus Worthing, MD, FACP, FACR.1
For example, between 2009 and 2014, when office-based reimbursement was sharply declining, 2.3 million fewer DXA tests were performed.2 Between 2008 and 2015, Dr. Worthing says, osteoporosis diagnoses dropped by 17%, with a concomitant increase in surprise hip fractures (no prior osteoporosis diagnosis) of 14%.